Induction and inhibition of crystallization in drug-in-adhesive-type transdermal patches

Pharmaceutical Research

Volumn 30, Issue 2, 2013, Pages 562-571

  Jain, Piyush ^a   Banga, Ajay K ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

adhesive; crystallization; die cutting; levonorgestrel; transdermal

Indexed keywords

DRUG ADDITIVE; LEVONORGESTREL; POLOXAMER;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DIFFUSION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; ENTHALPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TEMPERATURE SENSITIVITY; TRANSDERMAL PATCH;

CONTRACEPTIVES, ORAL, SYNTHETIC; CRYSTALLIZATION; DRUG STORAGE; EXCIPIENTS; LEVONORGESTREL; POLOXAMER; POVIDONE; SOLUBILITY; TEMPERATURE; TRANSDERMAL PATCH;

EID: 84873432351     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0901-7     Document Type: Article

References (29)

1. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-8.
2. Minghetti P, Cilurzo F, Pagani S, Casiraghi A, Assandri R, Montanari L. Formulation study of oxybutynin patches. Pharm Dev Technol. 2007;12(3):239-46.
3. Kim JH, Choi HK. Effect of additives on the crystallization and the permeation of ketoprofen from adhesive matrix. Int J Pharm. 2002;236(1-2):81-5.
4. Kotiyan PN, Vavia PR. Eudragits: role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol. Eur J Pharm Biopharm. 2001;52(2):173-80.
5. http://www.neupro.com/Returning/Returning.asp (03/01/2012).
6. Cilurzo F, Minghetti P, Casiraghi A, Tosi L, Pagani S, Montanari L. Polymethacrylates as crystallization inhibitors in monolayer transdermal patches containing ibuprofen. Eur J Pharm Biopharm. 2005;60(1):61-6.
7. Jain P, Banga AK. Inhibition of crystallization in drug-in-adhesive-type transdermal patches. Int J Pharm. 2010;394(1-2):68-74.
8. Lipp R. Selection and use of crystallization inhibitors for matrix-type transdermal drug-delivery systems containing sex steroids. J Pharm Pharmacol. 1998;50(12):1343-9.
9. Chen G-S, Kim D-D, Chien YW. Dual-controlled transdermal delivery of levonorgestrel and estradiol: enhanced permeation and modulated delivery. J Control Release. 1995;34:129-43.
10. Chen S, Singh J. In vitro release of levonorgestrel from phase sensitive and thermosensitive smart polymer delivery systems. Pharm Dev Technol. 2005;10(2):319-25.
11. Harrison LI, Zurth C, Gunther C, Karara AH, Melikian A, Lipp R. Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations. Drug Dev Ind Pharm. 2007;33(4):373-80.
12. Bruni G, Berbenni V, Milanese C, Girella A, Marini A. Drug-excipient compatibility studies in binary and ternary mixtures by physico-chemical techniques. J Therm Anal Calorim. 2010;102:193-201.
13. Dohner JW, Bura SA. Improved method for preventing crystal formation in a dispersion of a liquid in a matrix. WO/1997/020550, 1997.
14. Isaac BF, Fabio SA, Evaristo SFJ. Inhibition of crystallization in transdermal devices US6465005, 2002.
15. http://transdermal.henkel.com/ (03/02/2012).
16. Myatt R, Oladiran G, Batchelor H. Solubility calculator. Drug Delivery Technol. 2008;8(3):56-9.
17. Van Laarhoven JA, Kruft MA, Vromans H. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm. 2002;232(1-2):163-73.
18. Paul DR, McSpadden SK. Diffusional release of a solute from a polymeric matrix. J Membr Sci. 1976;1:33-48.
19. Jain SK, Chourasia MK, Sabitha M, Jain R, Jain AK, Ashawat M, et al. Development and characterization of transdermal drug delivery systems for diltiazem hydrochloride. Drug Deliv. 2003;10(3):169-77.
20. Gupta JRD, Irchhiaya R, Garud N, Tripathi P, Dubey P, Patel JR. Formulation and evaluation of matrix type transdermal patches of glibenclamide. Int J Pharm Sci Drug Res. 2009;1(1):46-50.
21. Leichtnam ML, Rolland H, Wuthrich P, Guy RH. Impact of antinucleants on transdermal delivery of testosterone from a spray. J Pharm Sci. 2007;96(1):84-92.
22. Reid ML, Brown MB, Jones SA. Manipulation of corticosteroid release from a transiently supersaturated topical metered dose aerosol using a residual miscible co-solvent. Pharm Res. 2008;25(11):2573-80.
23. Variankaval NE, Jacob KI, Dinh SM. Polymorphism of 17-beta estradiol in a transdermal drug delivery system. J Mater Sci Mater Med. 2002;13(3):271-80.
24. Pattnaik S, Swain K, Mallick S, Lin Z. Effect of casting solvent on crystallinity of ondansetron in transdermal films. Int J Pharm. 2011;406(1-2):106-10.
25. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm. 2001;212(2):213-21.
26. Schulz M, Fussnegger B, Bodmeier R. Influence of adsorbents in transdermal matrix patches on the release and the physical state of ethinyl estradiol and levonorgestrel. Eur J Pharm Biopharm. 2011;77(2):240-8.
27. Van Buskirk GA, Arsulowicz D, Basu P, Block L, Cai B, Cleary GW, et al. Passive transdermal systems whitepaper incorporating current Chemistry, Manufacturing and Controls (CMC) Development Principles. AAPS PharmSciTech. 2012;13(1):218-30.
28. http://www.neupro.com/documents/Neupro-FDA-ENG.pdf (03/03/2012).
29. Foreman P, Luciano A, Yang H, Jacobson S. Transdermal adhesives: predicting drug solubility in transdermal adhesives. Drug Delivery Technol. 2005;5(7):46-51.